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Abstract
Introduction: Hypoxia and T-helper cell 1 (Th1) cytokine-driven inflammation are key features of rheumatoid
arthritis (RA) and contribute to disease pathogenesis by promoting angiogenesis. The objective of our study was to
characterise the angiogenic gene signature of RA fibroblast-like synoviocytes (FLS) in response to hypoxia, as well
as Th1 and T-helper cell 2 (Th2) cytokines, and in particular to dissect out effects of combined hypoxia and
cytokines on hypoxia inducible transcription factors (HIFs) and angiogenesis.
Methods: Human angiogenesis PCR arrays were used to screen cDNA from RA FLS exposed to hypoxia (1%
oxygen) or dimethyloxalylglycine, which stabilises HIFs. The involvement of HIF isoforms in generating the
angiogenic signature of RA FLS stimulated with hypoxia and/or cytokines was investigated using a DNA-binding
assay and RNA interference. The angiogenic potential of conditioned media from hypoxia-treated and/or cytokine-
treated RA FLS was measured using an in vitro endothelial-based assay.
Results: Expression of 12 angiogenic genes was significantly altered in RA FLS exposed to hypoxia, and seven of these
were changed by dimethyloxalylglycine, including ephrin A3 (EFNA3), vascular endothelial growth factor (VEGF),
adipokines angiopoietin-like (ANGPTL)-4 and leptin. These four proangiogenic genes were dependent on HIF-1 in
hypoxia to various degrees: EFNA3 >ANGPTL-4 >VEGF >leptin. The Th1 cytokines TNFa and IL-1b induced HIF-1 but
not HIF-2 transcription as well as activity, and this effect was additive with hypoxia. In contrast, Th2 cytokines had no
effect on HIFs. IL-1b synergised with hypoxia to upregulate EFNA3 and VEGF in a HIF-1-dependent fashion but, despite
strongly inducing HIF-1, TNFa suppressed adipokine expression and had minimal effect on EFNA3. Supernatants from
RA FLS subjected to hypoxia and TNFa induced fewer endothelial tubules than those from FLS subjected to TNFa or
hypoxia alone, despite high VEGF protein levels. The Th2 cytokine IL-4 strongly induced ANGPTL-4 and angiogenesis by
normoxic FLS and synergised with hypoxia to induce further proangiogenic activity.
Conclusion: The present work demonstrates that Th1 cytokines in combination with hypoxia are not sufficient to
induce angiogenic activity by RA FLS despite HIF-1 activation and VEGF production. In contrast, Th2 cytokines
induce angiogenic activity in normoxia and hypoxia, despite their inability to activate HIFs, highlighting the
complex relationships between hypoxia, angiogenesis and inflammation in RA.
Introduction
The inflammatory and invasive rheumatoid arthritis (RA)
synovial tissue is characterised by elevated levels of
inflammatory T-helper cell 1 (Th1) cytokines such as
IL-1b and TNFa (reviewed in [1]), as well as by lowered
oxygen tensions ranging between 2.4 and 4.4% oxygen
(18 to 33 mmHg) compared with 8.5 to 13.5% (65 to 103
mmHg) in healthy individuals [2]. Hypoxia in RA is
thought to arise as a consequence of thickening of the
synovial lining and infiltration by cells, predominantly
circulating T cells, B cells and macrophages. This even-
tually leads to formation of a thick multilayered granula-
tion tissue, termed pannus, which has propensity for
invasion at the interface of cartilage and bone, resulting
in progressive joint and soft tissue destruction [3,4].
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Oxygen delivery becomes progressively compromised
with increasing distances between the expanding tissue
mass of pannus and existing synovial vasculature, result-
ing in tissue hypoxia. Inflammation and hypoxia support
activation of local blood vessels and ongoing angiogenesis
in the synovial membrane, which is an important early
step in the pathogenesis of RA [5]. Counterintuitively,
despite attempts at restoring homeostasis through the
process of angiogenesis, tissue hypoxia prevails due to
the immaturity and dysfunctional nature of the newly
formed vessels [6].
There is considerable evidence to suggest that angio-
genesis and chronic inflammation are co-dependent in
inflammatory diseases such as RA (reviewed in [7]). For
instance, increased blood vessel formation, and hence an
increased surface area of vessels, can maintain the
chronic inflammatory state through increased production
of cytokines and by allowing inflammatory cells to access
the inflamed synovial tissue. Moreover, angiogenesis sus-
tains the supply of nutrients and oxygen to the hyperpro-
liferating inflamed RA tissue. Conversely, inflammatory
mediators such as Th1 cytokines and growth factors
secreted by the infiltrating inflammatory cells are known
to have both direct and indirect angiogenic effects on
endothelial cells and resident RA synovial cells, respec-
tively [8,9]. These interdependent mechanisms underly-
ing angiogenesis and inflammation in RA explain why
biologics targeting inflammatory cytokines also reduce
angiogenesis and why induction of angiogenesis is asso-
ciated with increased synovial inflammation and pannus
formation [6,10]. Likewise, angiogenesis blockade has
been shown to reduce inflammation [11].
Major transcription factors that may constitute a link
between inflammation, hypoxia and angiogenesis are the
heterodimeric hypoxia-inducible factor (HIF)-1 and
HIF-2. These are best known as the principal mediators
of cellular responses to hypoxia, such as angiogenic
responses involving the well-known angiogenic factor
vascular endothelial growth factor (VEGF) and a plethora
of other angiogenic genes [12]. Both HIF isoforms accu-
mulate in circumstances of oxygen deprivation, which is
associated with decreased degradation of the HIF-1a and
HIF-2a subunits. This enables the transcription of HIF
target genes, characterised by the presence of hypoxia-
response elements (HRE). HIF-1a is ubiquitously
expressed whereas HIF-2a is expressed in a more limited
fashion. It is becoming clear that the two isoforms have
overlapping as well as unique roles in hypoxia signalling,
which are achieved through differential regulation and
specific target gene selection. HIF-1a, HIF-2a and VEGF
are all overexpressed in the synovial lining and stromal
cells in rheumatoid synovia compared with normal syno-
via [13]. Moreover, the number of HIF-1a-positive cells
has been shown to correlate strongly with the number of
blood vessels in RA synovial tissue and with inflamma-
tory endothelial cell infiltration, cell proliferation and the
synovitis score [14].
In parallel to the oxygen-dependent pathway, HIF-1a
and HIF-2a subunits are also regulated by inflammatory
cytokines such as IL-1b and TNFa under normoxic con-
ditions via receptor-mediated signals. In contrast to the
specific stabilisation of HIF-a protein occurring under
hypoxic conditions, Th1 cytokines appear to act on sev-
eral regulatory levels and have been reported to stimulate
HIF-a mRNA synthesis and stability in macrophages and
RA fibroblast-like synoviocytes (FLS) [15,16], and to
induce changes in HIF-1a levels and/or transcriptional
activation in a number of cell types [17,18]. HIF-1a stabi-
lisation by Th1 cytokines has been demonstrated to be
partially mediated by the NFB and p38 mitogen-acti-
vated protein kinase signalling pathways in human articu-
lar chondrocytes [19], and by phosphatidylinositol
3-kinase/Akt and MEK1/2 inhibitor activation in RA FLS
[16,20]. Importantly, Th1 cytokines have been demon-
strated to synergise with hypoxia to induce HIF-1 protein
and activity in HepG2 cells, a human hepatoma cell line
[18], and to synergise with hypoxia and the hypoxia
mimetic CoCl2 to induce HIF-1a mRNA and protein,
respectively, in RA FLS [16,21]. Inflammatory cytokines
and hypoxia were also shown able to act together to aug-
ment hypoxia-mediated upregulation of VEGF secretion
in RA FLS [22]. As the composition of the RA synovium
includes elevated levels of inflammatory cytokines on a
hypoxic background, a strong and continuous presence
of HIF transcription factors is favoured through increased
HIF-a mRNA levels and protein stabilisation. HIFs thus
represent a key convergence point that integrates the cel-
lular response of the RA synovium to low oxygen tension
and inflammatory cytokines, and thereby drives synovial
inflammation and angiogenesis.
Th1 and T-helper cell 2 (Th2) cytokines were recently
demonstrated to have differential effects on HIF isoforms.
For instance, in macrophages Th1 cytokines induce
HIF-1a and Th2 cytokines induce HIF-2a mRNA, and
this differential regulation of HIF-1a versus HIF-2a acts
to respectively either increase or suppress nitric oxide
synthesis and thus to control overall nitric oxide availabil-
ity [15]. In contrast to Th1 cytokines, anti-inflammatory
Th2 cytokines are found at very low levels in RA joints
and synovial fluid but they may hold an important thera-
peutic role in RA via HIFs. For instance IL-4, the signature
cytokine of CD4+ Th2 cells, is known to reduce the pro-
duction of Th1 cytokines by RA synovium [23] - and IL-4
has been used in vivo as a treatment for a number of
experimental autoimmune diseases in animals, including
collagen-induced arthritis (CIA) [24]. By suppressing Th1
cytokine levels, IL-4 may indirectly lower HIF activation
and hence the degree of synovial angiogenesis. Despite
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these interesting aspects, the downstream effects of stimu-
lating RA synovial cells with Th1 versus Th2 cytokines in
a hypoxic environment have not yet been investigated
with regard to HIF regulation and downstream angiogenic
gene expression.
The use of antibodies to cytokines as pharmacological
antagonists has revealed the profound effects of anti-
TNFa treatment in reducing inflammation and joint
destruction in RA. Despite the clear efficacy of anti-TNFa
therapy, the actual mechanisms by which TNF-blocking
agents are able to obtain these effects are still incompletely
understood. In clinical trials using the TNFa inhibitor
infliximab, reduced synovial angiogenesis and vascularity
appears to be an effect associated with the neutralisation
of TNFa [10]. As HIFs regulate a plethora of downstream
angiogenic factors including VEGF, in response to hypoxia
and inflammatory cytokines, the efficacy of anti-TNFa
therapy could, at least in part, be due to a reduction in the
activation of HIF leading to decreased angiogenesis and
less immature synovial vessels in RA patients.
In the present study, we chose to examine the impact
of combined Th1 or Th2 cytokines and hypoxia on the
angiogenic signature of RA FLS, focusing particularly on
the role of HIF isoforms in the expression of downstream
angiogenic genes. RA FLS was the chosen study target
due to its recognised role in RA pathogenesis, where it
contributes to bone and cartilage breakdown through the
acquisition of what appears to be a transformed pheno-
type [4,25]. Moreover, as this cell type makes up the bulk
of the expanding RA synovial membrane tissue [26], it is
likely to be exposed to various degrees of hypoxia and
inflammatory cytokines simultaneously. We investigated
the effect of Th2 cytokines on the angiogenic signature of
RA FLS in normoxia and hypoxia in an attempt to eluci-
date the potential that Th2 cytokines could ameliorate
autoimmune disease by influencing angiogenesis.
Materials and methods
Isolation and culture of cells from human RA tissue
Total RA synovial membrane cells and FLS were derived
from synovial membranes of patients at the Royal Free
Hospital (London, UK) who met the American College of
Rheumatology 1987 criteria for RA [27]. Full ethical
approval was granted for the project (Local Ethics
Research Committee EC2003-64). Preoperative informed
consent was obtained in all cases.
The RA cell cultures were isolated and cultured as pre-
viously published [28,29]. The disaggregated total syno-
vial membrane cell cultures were used directly in
experiments. Alternatively, after overnight incubation,
nonadherent cells were removed to allow overgrowth of
FLS. The purity of the FLS culture was confirmed at pas-
sage 3 by immunohistochemistry with monoclonal anti-
human-Fibroblast-Surface Protein 1 antibody (Abcam,
Cambridge, UK) and determined to be >98%. FLS and
normal human skin fibroblasts (HSF; Lonza, Walkersville,
MD, USA) were cultured in DMEM containing 10% foe-
tal bovine serum, 4.5 g/l glucose and L-glutamine, sup-
plemented with 100 U/ml penicillin and 100 μg/ml
streptomycin (PAA Laboratories, Coelbe, Germany). RA
FLS were used between the third and sixth passages.
Experimental setup and siRNA transfection
RA FLS cell cultures were starved in serum-free DMEM
overnight (total synovial membrane cell cultures were
used directly in complete medium) and subsequently
subjected to a hypoxic gas mixture (1% oxygen, 5% CO2,
94% N2) for the desired length of time. Alternatively,
1 mM dimethyloxalylglycine (DMOG; Biomol Interna-
tional, Exeter, UK) or dimethyl sulfoxide (DMSO) (as
vehicle) or cytokines IL-4, IL-1b, IFNg (Peprotech, Lon-
don, UK), TNFa (R&D Systems, Minneapolis, MN, USA)
and IL-13 (Abcam) at 10 ng/ml were used to stimulate
cells. Total RNA was isolated and the corresponding
cDNA was used for quantitative PCR analysis. The cell
supernatants were collected for ELISA and for testing in
a functional angiogenesis assay.
Knockdown of genes was performed with siRNA
against HIF-1a (5’-(AGCAGGUAGGAAUUGGAA-
CAUU)RNA(tt)DNA-3’) and/or HIF-2a (5’-(GCGA-
CAGCUGGAGUAUGAAUU)RNA(tt)DNA-3’) at a final
concentration of 10 nM (MWG, Ebersberg, Germany) in
Opti-MEM I Reduced Serum Medium (Invitrogen, Pais-
ley, UK) using Lipofectamine 2000 (Invitrogen). An
siRNA oligonucleotide against luciferase mRNA (siLuc)
was used as a negative control, as well as oligonucleo-
tides with the scrambled sequence of siHIF-1a or siHIF-
2a (data not shown).
RNA isolation and quantitative PCR
RNA was isolated using the Total RNA E.Z.N.A™ EaZy
Nucleic Acid Isolation kit (VWR, Batavia, IL, USA) and
was DNase treated (Ambion Ltd, Paisley, UK). First-
strand cDNA was synthesised using random primers
(Invitrogen) and Moloney Murine Leukaemia Virus
reverse transcriptase (Promega, Southampton, UK).
Diluted cDNA was added to SYBR®Green I Jump-
Start™ Taq Ready MIX™ (Sigma-Aldrich, Poole, UK),
primer mix and nuclease-free water. Exon-spanning
PCR primers (MWG) were designed using Primer 3
(Table 1). All primers were validated prior to use. Pri-
mers for the housekeeping gene 18S ribosomal RNA
and acidic ribosomal protein (data not shown) were
used to normalise samples.
Quantitative PCR was performed with the following
programme: pre-incubation at 50°C for 2 minutes, initial
denaturation at 95°C for 5 minutes, 40 cycles of dena-
turation at 95°C for 10 seconds, annealing at 60°C for
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30 seconds, elongation at 72°C for 30 seconds, and a
20-second final extension step. Rotor-Gene Software
version 6.0 was used to analyse the data (Qiagen, Craw-
ley, UK). The comparative cycle threshold (Ct) method
(2-ΔΔCt model) was used to calculate relative fold-
changes in gene expression [30].
PCR array
Human Angiogenesis RT2 Profiler™ PCR Arrays (Tebu-
Bio, Peterborough, UK) were used to screen cDNA from
human RA FLS exposed to 21% or 1% oxygen and to
DMSO or 1 mM DMOG. The PCR array was used
according to manufacturers’ protocol on an ABI 7700
sequence detector (Applied Biosystems, Foster City, CA,
USA) using SYBR green technology (TebuBio). Every
sample was run on duplicate PCR array plates and the
relative quantification of mRNA was performed using the
2-ΔΔCt model and normalised to the average of two or
more housekeeping genes on the PCR array.
Protein measurement by ELISA
Leptin and ANGPTL-4 released into the medium by RA
FLS were measured using ELISA duosets (R&D Systems).
VEGF was measured using reagents from Becton Dickin-
son (Oxford, UK) and antibodies from R&D Systems.
Western blotting
Total protein extracts were separated on NuPAGE Novex
Tris-Acetate pre-cast gels 3 to 8% (Invitrogen) under
reducing conditions and proteins were blotted onto poly-
vinylidene fluoride membranes (Perkin Elmer, Waltham,
MA, USA). The membranes were blocked with 0.01%
Tween 20, PBS and 5% nonfat milk for 1 hour at room
temperature, washed and incubated for 2 hours with
either anti-human HIF-1a mouse mAb at 1:250 (BD
Transduction Laboratories, Oxford, UK) or anti-human
a-tubulin mouse mAb at 1:10,000 (Sigma-Aldrich). The
membranes were washed and incubated for 1 hour at
room temperature with horseradish peroxidase-coupled
rabbit anti-mouse IgG at 1:5,000 (Dakocytomation,
Glostrup, Denmark), and developed using ECL plus and
hyper-film ECL (GE Healthcare, Chalfont St Giles, UK).
Nuclear extraction and measurement of HIF-1 DNA
binding activity
HIF-1 DNA binding activity was determined in RA FLS
nuclear extracts. Nuclear extraction was performed
according to the manufacturer’s protocol (Active Motif,
Carlsbad, CA, USA) and the protein concentration was
determined using the BCA method. To measure HIF-1
DNA binding activity following stimulation of cells with
low oxygen levels and/or cytokines, the nuclear extracts
were tested using the ELISA-based TransAM HIF-1
Transcription Factor Assay (Active Motif). A secondary
horseradish peroxidase-conjugated antibody and enzyme
substrate included in the assay kit were used before
HIF-1 binding to HRE was measured by absorbance at
450 nm. Each sample to be assayed for HIF-1 DNA
binding was tested in duplicate. The specificity of HIF-1
binding to the HRE-coated wells was confirmed by com-
petition experiments where either wild type or mutated
HRE oligonucleotides (Active Motif) were added to the
wells along with the nuclear extracts to be tested (data
not shown).
Matrigel tube formation assay
This assay was performed in a 96-well plate with 50 µl
Growth Factor Reduced Matrigel per well (VWR, Lutter-
worth, UK) that was left to gel for 45 minutes at 37°C.
Human microvascular endothelial cell (HMEC)-1 (Center
for Disease Control and Prevention, Atlanta, GA, USA)
was cultured in RPMI containing 5% foetal bovine serum
and supplemented with 100 U/ml penicillin and 100 μg/ml
streptomycin (PAA Laboratories). The cells were used for
matrigel assays when 80% confluent without prior starva-
tion. Cells were dispersed with trypsin and 15,000 cells
were loaded into each well in 100 µl full-growth medium.
Then 100 µl conditioned medium from RA FLS stimulated
with cytokines and/or subjected to hypoxia for 24 hours
were added per well and the assay was incubated at 37°C
for 4 to 6 hours until sufficient tube formation was visible
with a microscope. Direct effects of recombinant TNFa
and IL-4 were tested by adding 100 μl of 10 ng/ml cytokine
in fibroblast medium per well in triplicate. The tubules
were fixed with 4% para-formaldehyde (Sigma-Aldrich),








18S ribosomal RNA 5´-GTAACCCGTTGAACCCCA-3´ 5´-CCATCCAATCGGTAGTAGCG-3´
ANGPTL-4, angiopoietin-like-4; EFNA3, ephrin A3; HIF, hypoxia-inducible factor; VEGF, vascular endothelial growth factor.
Larsen et al. Arthritis Research & Therapy 2012, 14:R180
http://arthritis-research.com/content/14/4/R180
Page 4 of 18
washed in PBS and stained for 5 minutes with 50 µl Gram’s
Crystal Violet (Sigma-Aldrich), and the washing step was
then repeated.
Images were captured with a camera (QICAM FAST;
QImaging,Surrey, BC, Canada) attached to a microscope
(CKX41 Olympus,Southend-on-Sea, UK) and the matrigel
assay was scored using AngioSys Image Analysis software
(TCS Cell Works, Buckingham, UK). This program pro-
vides quantitative measurement of tubule development in
images captured from the 96-well plate, analysing the
three parameters of total tubule number, number of tubule
junctions and percentage of field area covered by tubules.
Each experimental condition was tested in triplicate wells
with a single picture captured from the centre of each
well. The images were blinded prior to analysis.
Statistical analysis
Data were analysed using Prism software (Graph Pad Soft-
ware, San Diego, CA, USA). P values were determined
using a paired two-tailed t test assuming unequal variances
or where indicated a one-way analysis of variance with
Bonferroni’s multiple comparison test.
Results
PCR arrays identify seven genes as hypoxia-regulated
in a HIF-dependent manner in RA FLS
To determine which angiogenic factors are produced by
RA FLS in response to hypoxia, we isolated RA FLS
from synovial tissue of five patients, cultured them for 4
or 24 hours under either hypoxic conditions (1% oxy-
gen) or normoxic conditions (21% oxygen), and
screened the cDNA using a Human Angiogenesis RT2
Profiler™ PCR array. These arrays include 84 genes that
have all been implicated in the process of angiogenesis
in various cell types and settings. (See Additional file 1
for a table showing as an example the results from the
screening of hypoxic FLS from one RA patient.
Of the 84 known angiogenic genes on the array, the
mRNA level of four genes changed after 4 hours -
namely ephrin A3 (EFNA3; threefold, P < 0.05), VEGF
(sixfold, P < 0.05), and adipokines angiopoietin-like
(ANGPTL)-4 (21-fold, P < 0.01) and leptin (59-fold, P <
0.001) (Figure 1a). After 24 hours, 12 genes were signifi-
cantly altered in RA FLS in response to hypoxic expo-
sure from all patients (≥2-fold increase or decrease in all
five patients at P < 0.05) (Figure 1b). The two genes
that were induced most dramatically after 24 hours of
hypoxia were leptin (108-fold, P < 0.001) and ANGPTL-
4 (12-fold, P < 0.05). This induction was greater than
that observed for VEGF (eightfold, P < 0.05), a well-
characterised hypoxia-regulated gene. The induction of
ANGPTL-4 and leptin by hypoxia is in agreement with
a recent microarray expression study in RA FLS [31]. In
addition to ANGPTL-4 and leptin, the expression of a
receptor protein tyrosine kinase, EFNA3, was also
increased by hypoxia (twofold, P < 0.01). Furthermore, a
significant reduction was seen in the mRNA of HIF-1a,
plasminogen activator urokinase, , heart and neural crest
derivatives expressed 2, C-fos-induced growth factor
(VEGF D), chemokines CCL-11 and CXCL-5, and
heparanase (Figure 1b). The largest reduction in gene
expression (ninefold, P < 0.05) was seen for CCL-11
(which encodes the protein eotaxin, best known for its
role in neutrophil chemotaxis).
To establish whether the hypoxia-regulated genes were
induced in a HIF-dependent or HIF-independent man-
ner, we stimulated FLS from three RA patients for 24
hours with DMOG, resulting in similar but not identical
responses to hypoxia (Figure 1c). DMOG is a nonspecific
inhibitor of prolyl hydroxylases leading to both HIF-1a
and HIF-2a accumulation as the subunits no longer
become hydroxylated and targeted for proteosomal
degradation (Figure 1d). DMOG induced changes in the
expression of 11 genes, seven of which were also hypoxia
responsive (Table 2). These included leptin (85-fold, P <
0.001), ANGPTL-4 (48-fold, P < 0.01), EFNA3 (ninefold,
P < 0.05) and VEGF (31-fold, P < 0.05), which were upre-
gulated, and HIF-1a (twofold, P < 0.05) that was downre-
gulated, implicating HIF transcription factors as
regulators of these hypoxia-responsive genes. The HIF-
mediated downregulation of HIF-1a mRNA in hypoxic
RA FLS confirms the findings of a parallel study (H Lar-
sen, B Muz, M Feldmann, EM Paleolog, unpublished
data). In addition, genes that were altered in response to
DMOG but not to hypoxia included increased ephrin B2,
reduced inhibitor of DNA-binding 3, dominant negative
helix-loop-helix protein, neuropillin 2 and CCL-2,
demonstrating that the effects of DMOG and hypoxia are
not interchangeable.
As the constituents of RA joints are invariably of mixed
cell types including FLS as well as T cells, B cells, endothe-
lial cells and macrophages, we tested the relevance of our
findings by subjecting total cell isolates from synovial
membranes of RA patients to 1% oxygen for 24 hours to
compare data from RA FLS. Gene expressions for leptin,
ANGPTL-4, EFNA3 and VEGF were significantly upregu-
lated (132-fold, 10-fold, threefold and sevenfold increase,
respectively) following 24 hours of stimulation with
hypoxia, mirroring responses obtained from RA FLS alone
(Figure 1e). Furthermore, we exposed FLS to a range of
oxygen tensions (1 to 10% oxygen) and found that the
genes of interest (ANGPTL-4, VEGF, leptin, EFNA3)
change in a similar fashion at 3%, the median oxygen ten-
sion measured in RA synovium when compared with 1%
oxygen, albeit to a lesser extent (see Additional file 2). At
10% oxygen, which is the median oxygen tension found in
healthy synovium, we no longer observed any effect on
angiogenic gene expression.
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Figure 1 Angiogenesis RT² Profiler™ PCR Array data and expression analysis of human rheumatoid arthritis cells. PCR arrays were used
with cDNA from rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) from five RA patients and incubated for either (a) 4 hours or (b)
24 hours in 1% oxygen (hypoxia) and (c) from three RA patients exposed to 1 mM dimethyloxalylglycine (DMOG) for 24 hours. Values are fold-
change versus normoxia (21% oxygen) or dimethyl sulfoxide (DMSO) control and were analysed against housekeeping gene b-actin, 18S
ribosomal RNA, hypoxanthine phosphoribosyltransferase 1 and 60S ribosomal protein L13a. Genes significantly increased or decreased by a factor
≥2 (P < 0.05, dotted line) in all patients are shown. Data are mean ± standard error of the mean and were analysed by paired t test of ΔCt
values, comparing normoxia versus hypoxia (a and b) or DMSO control versus DMOG (c). (d) Western blotting demonstrates induction of
hypoxia-inducible factor (HIF)-1a and HIF-2a in total protein lysates from RA FLS in response to 1% oxygen or 1 mM DMOG for 24 hours. An
antibody against a-tubulin was used as a loading control. A lane irrelevant to the study was removed as indicated by the line to show lanes of
interest adjacent to one another. (e) Freshly dissociated total human RA synovial membrane cells from four patients were analysed for
expression of vascular endothelial growth factor (VEGF), leptin, ephrin A3 (EFNA3) and angiopoietin-like (ANGPTL)-4 using quantitative PCR.
Changes in mRNA are expressed as fold-change relative to levels under 21% oxygen set as 1.0 (dotted line). *P < 0.05, **P < 0.01, ***P < 0.001.
EFNB2, ephrin B2; FIGF, C-fos-induced growth factor (VEGF D); HAND2, Heart and neural crest derivatives expressed 2; HPSE, heparanase; ID3,
inhibitor of DNA-binding 3, dominant negative helix-loop-helix protein; NRP2, neuropillin 2; PLAU, plasminogen activator urokinase.
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Hypoxia induces leptin, ANGPTL-4 and ephrin A3 in a
HIF isoform-dependent manner
As leptin, ANGPTL-4 and EFNA3 were the genes that
were upregulated to the greatest extent on the array by
hypoxia and also by the HIF activator DMOG, these genes
were selected for further investigation. Importantly, we
wanted to elucidate which of the two HIF isoforms, HIF-1
or HIF-2, might be involved in the induction of these
genes. Leptin and ANGPTL-4 have previously been
reported to be regulated by hypoxia in a HIF-1-dependent
manner in adipocytes, human skin fibroblasts, HeLa cells,
and MCF-7 breast cancer cells (leptin) [32-34], and in
cadiomyocytes (ANGPTL-4) [35], but none of these stu-
dies addressed the involvement of the HIF-2 isoform.
Induction of EFNA3 by HIFs has not previously been
investigated. To examine the relative importance of either
HIF isoform in inducing angiogenic responses, we used
siRNA technology to knock down HIF-1a and HIF-2a
individually or in combination. The efficiency of HIF
knockdown using siRNA oligonucleotides was confirmed
at the mRNA level using quantitative PCR, with HIF-1
reduced by 74% using siHIF-1 (P < 0.001 versus siLuc)
and 80% for HIF-2 using siHIF-2 (P < 0.001 versus siLuc),
and at the protein level by Wblotting (see Additional file 2).
We found hypoxia-induced leptin to be predominantly
dependent on HIF-2 as knockdown of HIF-2a resulted in
66% reduction in leptin expression relative to siLuc, while
the effect of siHIF-1a was more modest (33% reduction in
leptin expression; Figure 2a). Addition of a combination of
siHIF-1a and siHIF-2a almost completely abolished
hypoxia-induced leptin expression, demonstrating the
involvement of both isoforms (98% reduction relative to
siLuc). In contrast, HIF-1 and HIF-2 appeared to contri-
bute more evenly to ANGPTL-4 induction, as HIF-1a or
HIF-2a knock down resulted in reduction of ANGPTL-4
expression by 52% and 40%, respectively, relative to cells
transfected with siLuc (Figure 2c). Accordingly, a
combination of siHIF-1a and siHIF-2a had an even
greater knockdown effect on ANGPTL-4 expression of
75% compared with siLuc transfected cells. VEGF expres-
sion was also dependent on both HIF isoforms (Figure 2e);
however, knock down of HIF-2a seemed to have a slightly
stronger impact on the VEGF transcript level (57% reduc-
tion) than knock down of HIF-1a (44% reduction). Knock
down of both HIF isoforms reduced VEGF expression
even further (78% reduction). Interestingly, EFNA3
appeared to be regulated solely by HIF-1 (78% reduction
in EFNA3 expression by siHIF-1a relative to siLuc), where
HIF-2a knockdown was without effect on the hypoxia-
induced transcript level (Figure 2g). Hence the double HIF
isoform knockdown had no further effect compared with
HIF-1a knockdown. The HIF-isoform dependence in
hypoxia-treated cells was confirmed at the protein level
for leptin, ANGPTL-4 and VEGF, and gave rise to similar
results (Figure 2b,d,f). Western blotting for EFNA3 was
unsuccessful - probably due to the protein being simulta-
neously downregulated in hypoxia, which was previously
demonstrated in human umbilical vein endothelial cells
[36].
Th1 cytokines specifically drive a HIF-1 isoform response
by RA FLS
As demonstrated above, hypoxia stabilises HIF-1a and
HIF-2a protein subunits, thereby enabling the formation
of active HIF transcription factors and subsequent pro-
duction of angiogenic factors. As the RA synovial tissue
in patients is characterised by elevated levels of inflam-
matory Th1 cytokines in addition to hypoxia, we next
investigated the effect of a selection of Th1 and Th2
cytokines, relevant to RA disease, on HIF-1 and HIF-2
in RA FLS. Cytokines have previously been shown to
induce HIFs, and selective induction of HIF-1 by Th1
cytokines and of HIF-2 by Th2 cytokines has been
demonstrated in macrophages [15] but has not been
Table 2 Genes significantly upregulated or downregulated by hypoxia and/or dimethyloxalylglycine in human
rheumatoid arthritis fibroblast-like synoviocytes
Genes that change only in response to
hypoxia
Genes that change only in response to
DMOG
Genes that change in response to hypoxia and
DMOG
TGF-b1 (2*) NRP2 (-2*) VEGF (8*/31*)
HPSE (-2*) ID3 (-3*) PLAU (-2*/-2*)
FIGF (-2*) EFNB2 (5*) LEP (108***/85***)
CXCL-5 (-2*) CCL2 (-4*) HIF1A (-2*/-2*)
CCL-11 (-9*) HAND2 (-2*/-6*)
EFNA3 (2*/9*)
ANGPTL4 (12**/48**)
Genes significantly upregulated or downregulated by a factor ≥2. Genes from Figure 1b,c that change following 24 hours of hypoxia and in response to
stimulation with the hypoxia-inducible factor activator dimethyloxalylglycine (DMOG) in rheumatoid arthritis fibroblast-like synoviocytes from five and three
patients, respectively. Data presented as mean fold-change. Genes that changed significantly (P < 0.05) by a factor ≥2-fold were analysed by paired Student’s t
test comparing ΔCt values: *P < 0.05, **P < 0.001, ***P < 0.001. ANGPTL, angiopoietin-like; EFNA3, ephrin A3;EFNB2, ephrin B2; FIGF, C-fos-induced growth factor
(VEGF D); HAND2, Heart and neural crest derivatives expressed 2; HPSE, heparanase; ID3, inhibitor of DNA-binding 3, dominant negative helix-loop-helix protein;
LEP, leptin; NRP2, neuropillin 2; PLAU, plasminogen activator urokinase; TGF, transforming growth factor; VEGF, vascular endothelial growth factor.
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Figure 2 Hypoxia-induced hypoxia-inducible factor isoform dependence of angiogenic genes in human rheumatoid arthritis fibroblast-like
synoviocytes. Hypoxia-induced hypoxia-inducible factor (HIF) isoform dependence of ephrin A3 (EFNA3), angiopoietin-like (ANGPTL)-4, leptin and
vascular endothelial growth factor (VEGF) in human rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS). RA FLS were transiently transfected with
siRNA oligonucleotides complementary to hypoxia-inducible factor (HIF)-1a (siHIF-1a) or HIF-2a (siHIF-2a) or both simultaneously. An siRNA
oligonucleotide complementary to siLuc was used as control. The cell cultures were subsequently exposed to 1% oxygen (hypoxia) for 24 hours. Total
RNA was isolated and cDNA generated, and the mRNA level of (a) leptin and (c) ANGPTL-4, (e) VEGF and (g) EFNA3 was determined using
quantitative PCR. Changes in mRNA expressed as fold-change relative to levels in the siLuc transfected normoxic controls set as 1.0 (dotted line). The
secretion of (b) leptin, (d) ANGPTL-4 and (f) VEGF protein was measured using ELISA. Data expressed as mean ± standard error of the mean of ≥3
independent experiments with sample assayed in triplicate, and were analysed using one-way analysis of variance with Bonferroni’s post-hoc test for
multiple comparisons versus hypoxic siLuc transfected cells (*P < 0.05, **P < 0.01, ***P < 0.001).
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investigated in cells relevant to RA. In particular, we
examined the effect on HIFs of combining Th1 or Th2
cytokine stimulation with 1% oxygen on HIF activity
and HIFa protein levels.
To examine the effect of this combination we stimu-
lated RA FLS with 10 ng/ml of the Th1 cytokines TNFa
and IL-1b or the Th2 cytokines IL-4 and IL-13 in 21%
or 1% oxygen for 24 hours and investigated changes in
gene induction by quantitative PCR, Western blotting
and using a HIF DNA binding assay. By drawing com-
parisons with RA FLS subjected to hypoxia alone, we
found that HIF-1a transcript was induced by Th1 cyto-
kines TNFa and IL-1b (on average 7.4-fold and 3.5-fold,
respectively), but not by Th2 cytokines IL-4 (Figure 3a)
and IL-13 (data not shown). In contrast, HIF-2a mRNA
level was unaffected by stimulation with either Th1 or
Th2 cytokines (Figure 3b). In contrast, the mRNA of
both HIF-a isoforms was reduced by hypoxia by more
than 40% (Figure 3a,b), an effect we had also observed
on the PCR arrays for HIF-1a (Figure 1b,c). The effect
of the cytokines was confirmed at the activity level using
a TransAm assay from Active Motif, which measures
HIF-1 binding to HRE-coated wells. HIF-1 DNA binding
was induced ninefold by TNFa and 16.5-fold by IL-1b,
whereas IL-4 exerted a significantly negative effect on
HIF-1 binding under hypoxia (Figure 3c). In compari-
son, HIF-1 DNA binding was induced on average
between fourfold and 23-fold by hypoxia alone. IL-13
had no effect on HIF-1a or HIF-2a transcript induction,
protein level or HIF DNA binding activity (data not
shown). When we stimulated FLS with cytokines in
combination with 1% oxygen we found that both Th1
cytokines tested had an additive effect with hypoxia on
HIF-1 DNA binding.
Induction of HIF-1a protein by TNFa and lack
thereof in response to IL-4 was further shown by Wes-
tern blotting (Figure 3d). The additive effect of TNFa
and hypoxia on HIF-1 binding was also seen at the
HIF-1a protein level, demonstrating that HIF-1 serves
as a convergence point for hypoxia and inflammatory
signalling pathways in RA FLS. Unlike hypoxia that
induces both HIF isoforms in RA FLS, Th1 cytokines
thus drive activity of HIF-1 only. In contrast to what
has been shown in other cell types, the anti-inflamma-
tory Th2 cytokines did not appear to have any positive
effect on either of the HIF isoforms in RA FLS, whereas
IL-4 had an inhibitory effect on HIF-1 activity. Finally,
for comparison we tested the effect of IFNg, a Th1 cyto-
kine that is not associated with RA, on HIFa mRNA
levels in RA FLS. As observed with TNFa and IL-1b,
IFNg induced HIF-1a whereas it had a negative effect
on HIF-2a mRNA levels (see Additional file 2), suggest-
ing that RA FLS generally respond to Th1 cytokines by
upregulating HIF-1a.
Th1 cytokines enhance hypoxia-mediated induction of
ephrin A3 and VEGF but negatively regulate adipokines
ANGPTL-4 and leptin
We established above that only HIF-1 is induced by
both hypoxia and RA-associated Th1 cytokines and that
Figure 3 Th1 cytokines induce hypoxia-inducible factor-1
mRNA, protein and activity whereas Th2 cytokines have no
effect. Cell cultures were exposed to 10 ng/ml cytokine, 1% oxygen,
or left untreated for 24 hours. Total RNA was isolated and cDNA
generated, and the mRNA level of (a) hypoxia-inducible factor (HIF)-
1a and (b) HIF-2a was determined using quantitative PCR. Changes
in mRNA levels expressed as fold-change relative to levels in
untreated controls (dotted line). Data are mean ± standard error of
the mean and were analysed by paired t test of ΔCt values versus
control (*P < 0.05, ***P < 0.001). (c) HIF-1 binding to wells pre-
coated with human hypoxia-response element oligonucleotides in
response to 1% oxygen (hypoxia) and cytokine stimulation, alone or
in combination, was measured using nuclear extracts and a
TransAm HIF-1 DNA binding kit. DNA binding activity is expressed
as the optical density at 450 nm and represents the mean ±
standard deviation from three separate representative experiments.
Samples were analysed using one-way analysis of variance with
Bonferroni’s post-hoc test for multiple comparisons versus control
(†P < 0.05, ††P < 0.01, †††P < 0.001) or versus hypoxia alone (**P <
0.01, ***P < 0.001). (d) Western blots showing HIF-1a protein levels
in response to 1% oxygen, TNFa, IL-4 and cytokines in combination
with 1% oxygen for 24 hours. An antibody against a-tubulin was
used as a loading control.
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Th2 cytokines do not induce HIFs in RA FLS. We next
aimed to determine whether Th1 cytokine induction of
HIF-1 would induce expression of EFNA3, ANGPTL-4
and leptin similar to that observed in hypoxia. In parti-
cular, we wanted to investigate the effect of combined
Th1 cytokines and hypoxia on the expression of these
genes in RA FLS. We included IL-4 and IL-13 to deter-
mine whether Th2 cytokines had any HIF-independent
effects on the angiogenic genes investigated.
RA FLS were exposed to 10 ng/ml of either the Th1
cytokines TNFa and IL-1b or the Th2 cytokines IL-4
and IL-13, as single stimuli or in combination with 1%
oxygen for 24 hours. As hypoxia and Th1 cytokines
both induced HIF-1, our starting hypothesis was that
the HIF-1 target genes VEGF, ANGPTL-4 and EFNA3
(and to a lesser degree leptin) would be upregulated by
both conditions. Furthermore, we expected the additive
effect on HIF-1 DNA binding activity of hypoxia and
cytokines in combination would be transferred to induc-
tion of the HIF-1 target genes.
As expected, VEGF transcripts and protein were
induced by both Th1 cytokines IL-1b and TNFa, and the
observed effects were additive (TNFa) or even synergistic
(IL-1b) compared with hypoxia alone (Figure 4a,b) as was
previously reported [22]. Furthermore, both Th1 cyto-
kines had a modest effect on EFNA3 expression in nor-
moxia, with IL-1b interacting with hypoxia to generate
an additive effect upon EFNA3 expression whereas
combined TNFa with hypoxia had no further effect
(Figure 4f). In contrast to what we observed for VEGF
and EFNA3, the Th1 cytokines TNFa and IL-1b had
strong negative effects on ANGPTL-4 expression both as
single stimuli and in combination with hypoxia (Figure
4c,d), despite the ability of Th1 cytokines to induce
HIF-1 activity. TNFa also had an inhibitory effect on lep-
tin under hypoxic conditions, whereas IL-1b had no
effect on leptin expression (Figure 4e).
In contrast to the Th1 cytokines, IL-4 stimulation of RA
FLS led to a strong induction of ANGPTL-4 expression of
similar magnitude to that observed by hypoxic stimulation
alone. This effect was greatly amplified in the presence of
hypoxia and observed at both the mRNA and protein
levels (Figure 4c,d). IL-4 induced VEGF mRNA produc-
tion and protein secretion by the cells (Figure 4a,b),
whereas this cytokine had no effect on expression of
EFNA3 (Figure 4f). IL-13 had no effect on angiogenic gene
expression under normoxia or hypoxia (data not shown).
Interestingly, IL-4 also had anti-angiogenic effects because
it could almost completely abrogate hypoxia-induced lep-
tin (Figure 4e). Since we had already established that HIFs
are activated by Th1 cytokines and not by Th2 cytokines,
the observed effects of IL-4 on ANGPTL-4 and VEGF are
HIF independent. As was expected, we found Th1 cyto-
kine-mediated induction of VEGF to be mediated by
HIF-1, which we demonstrated using our siRNA oligonu-
cleotides against the HIF isoforms (Figure 5a). The nega-
tive effects of Th1 cytokines on ANGPTL-4 expression by
normoxic RA FLS was independent of HIF-1, as demon-
strated by HIF-1a isoform knock down that did not
restore basal ANGPTL-4 expression (Figure 5b). There
thus seems to be a differential regulation of HIF-1 target
genes by Th1 cytokines and hypoxia, although both
stimuli induce HIF-1.
We also examined whether the negative effect of Th1
cytokines on adipokine expression was specific to RA
FLS, and therefore RA disease related, by comparing our
findings with those obtained with normal HSF. TNFa
had a similar negative effect on leptin expression in
both cell types (see Additional file 2). In contrast, the
negative effect of TNFa on ANGPTL-4 previously
observed in RA FLS was absent in HSF, where a gradual
increase in ANGPTL-4 mRNA was observed with sti-
mulation time (see Additional file 2), suggesting that
ANGPTL-4 inhibition by TNFa is a pathological feature
of RA FLS.
Differential effects of Th1 and Th2 cytokines on HMEC-1
tubule formation in vitro
As demonstrated above, cytokines in combination with
hypoxia activate complex HIF-dependent and HIF-inde-
pendent responses by RA FLS. The eventual outcome of
tissue neovascularisation is dependent upon a delicate
balance between positive and negative regulators of
angiogenesis. To elucidate the functional significance of
the uncovered angiogenic gene signatures following cyto-
kine and hypoxia stimulation in RA FLS, we took FLS
supernatants and applied these in an in vitro angiogenesis
assay. Conditioned media from hypoxic RA FLS had a
marked proangiogenic effect on the endothelial cells
compared with supernatants from control RA FLS
(Figure 6a) and increased both the percentage of the total
field area covered by tubule-like structures (Figure 6b), as
well as the number of tubules (Figure 6c) and tubule
junctions (Figure 6d). The conditioned medium from RA
FLS pretreated with 10 ng/ml IL-4 for 24 hours also
induced angiogenesis, albeit to a lesser extent than
hypoxia (Figure 6a to d). We next investigated the angio-
genic drive of conditioned medium from cells co-stimu-
lated with IL-4 and hypoxia for 24 hours. We observed
this medium to be more angiogenic than supernatants
from cells subjected to either condition alone (Figure 6a),
with regard to both the increased percentage of total field
area covered by tubules as well as the number of tubules
and tubule junctions (Figure 6b to 6d).
The conditioned medium from RA FLS stimulated
with 10 ng/ml TNFa alone induced a modest angiogenic
response with HMEC-1 cells. Interestingly, the proan-
giogenic effect observed for hypoxia was absent when
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Figure 4 Proangiogenic/anti-angiogenic effects of Th1 and Th2 cytokines on rheumatoid arthritis fibroblast-like synoviocyte gene
expression. Cell cultures were exposed to 1% oxygen (hypoxia) and/or 10 ng/ml cytokine or left untreated for 24 hours. Total RNA was isolated
and cDNA generated, and the mRNA level of (a) vascular endothelial growth factor (VEGF), (c) angiopoietin-like (ANGPTL)-4, (e) leptin and
(f) ephrin A3 (EFNA3) was determined using quantitative PCR. Changes in mRNA expressed as fold-change relative to levels in untreated samples
set as 1.0 (dotted line). Secretion of (b) VEGF and (d) ANGPTL-4 protein was measured using ELISA. Data expressed as the mean ± standard
error of the mean of ≥3 independent experiments with samples assayed in triplicate. Samples analysed using one-way analysis of variance with
Bonferroni’s post-hoc test for multiple comparisons versus control normoxia (†P < 0.05, ††P < 0.01, †††P < 0.001) or versus hypoxia alone
(*P < 0.05, **P < 0.01,***P < 0.001).
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supernatants derived from cells exposed to TNFa and
hypoxia simultaneously were applied (Figure 6a to 6d).
These supernatants did not exhibit an increased angio-
genic effect over that of supernatants from unstimulated
RA FLS despite a much higher VEGF protein content
(Figure 4b).
We also tested the direct effects of recombinant TNFa
and IL-4 on tubule formation by the endothelial cells.
Both induced tubule formation in the matrigel assay (data
not shown). Although unlikely, unbound recombinant
cytokine in the normoxic supernatants could account for
the low angiogenic activity observed. This cannot, how-
ever, explain the reduction in tubule formation seen by
supernatants from hypoxic RA FLS co-stimulated with
TNFa, nor can it explain the larger angiogenic effect
observed with supernatants from hypoxic RA FLS stimu-
lated with IL-4.
Discussion
Angiogenesis in RA is an important hallmark of disease,
and the degree of angiogenesis and immature blood ves-
sel formation correlates with inflammation and disease
activity. Interestingly, therapies targeting Th1 cytokines
(for example, TNFa and IL-1b) have been shown to
reduce angiogenesis in addition to decreasing inflamma-
tion, whereas therapies using Th2 cytokines ameliorate
RA disease through less well described mechanisms
[6,24]. The aim of the present work was therefore to elu-
cidate how Th1 and Th2 cytokines affect angiogenesis in
RA, alone and in combination with hypoxia, a major driv-
ing force for angiogenesis in RA. Such research can con-
tribute to the understanding of how therapies directed
against Th1 cytokines directly and indirectly affect angio-
genesis, and also whether Th2 cytokines reduce disease
severity through an effect on angiogenesis. Moreover,
understanding how angiogenic factors are affected by
inflammatory and anti-inflammatory cytokines against a
background of synovial hypoxia may pave the way for
future optimisation of existing RA therapies to better tar-
get the dual aspect of RA disease, namely angiogenesis
and inflammation.
We specifically chose to focus on the differential effects
of Th1 versus Th2 cytokines and hypoxia on HIFs, the
master regulators of angiogenesis, and on the expression
of downstream angiogenic genes by RA FLS. FLS are
well-described contributors to inflammation and joint
degradation in RA [4,25]. As hypoxia and proinflamma-
tory cytokines typically co-exist within the RA synovium,
we were particularly interested in examining the angio-
genic effect of combined stimuli on RA FLS given that
both types of stimuli are capable of inducing HIF expres-
sion [16]. Although we demonstrated by PCR arrays that
several other novel angiogenic genes were significantly
altered in RA FLS exposed to hypoxia and the HIF activa-
tor DMOG, we focused on the genes EFNA3, leptin,
ANGPTL-4 and VEGF as surrogate markers of HIF-
induced genes and angiogenesis because they demon-
strated consistent and maximal induction on human
Figure 5 Th1-induced vascular endothelial growth factor but not angiopoietin-like-4 expression is dependent on hypoxia-inducible
factor-1. Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) were transiently transfected with siRNA oligonucleotides complementary to
hypoxia-inducible factor (HIF)-1a (siHIF-1a). An siRNA oligonucleotide complementary to siLuc was used as control. The cell cultures were
subsequently exposed to 10 ng/ml cytokines or left untreated for 24 hours. Changes in mRNA in response to IL-1b or TNFa of (a) vascular
endothelial growth factor (VEGF) and (b) angiopoietin-like (ANGPTL)-4 expressed as fold-change relative to levels in the siLuc transfected
untreated controls set as 1.0 (dotted line). Data expressed as the mean ± standard error of the mean of ≥3 independent experiments with
samples assayed in triplicate and analysed versus cytokine-treated siLuc transfected cells. *P < 0.05, **P < 0.01.
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Figure 6 Interactions of hypoxia and cytokines modulate induction of angiogenic activity by rheumatoid arthritis fibroblast-like
synoviocytes. Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) were cultured in normoxia (21% oxygen), hypoxia (1% oxygen) or with
10 ng/ml IL-4 or TNFa for 24 hours. Alternatively the cells were co-stimulated with cytokines whilst cultured in hypoxia to mimic the
environment in RA joints. Supernatants from these cultures were applied to wells of a 96-well plate containing growth factor-reduced matrigel
and pre-seeded human microvascular endothelial cell (HMEC)-1 cells and left to form tubules for 4 to 6 hours. (a) A single picture was captured
from the centre of each well with a camera (QICAM FAST; QImaging) attached to a microscope (CKX41; Olympus), with a representative example
for each condition shown here. Using AngioSys Image Analysis software we analysed several parameters of angiogenesis: (b) percentage of field
area covered by HMEC-1 tubules, (c) number of tubules, and (d) tubule junctions formed in the field area. Data expressed as the mean ±
standard error of the mean of ≥3 independent experiments with supernatants from each condition assayed in triplicate wells. Samples analysed
using one-way analysis of variance with Bonferroni’s post-hoc test for multiple comparisons versus control (*P < 0.05, **P < 0.01, ***P < 0.001).
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angiogenesis PCR arrays following hypoxia and DMOG
stimulation. The first gene, EFNA3, is a component of
the Eph/ephrin tyrosine kinase system and this receptor/
ligand system is associated with various signalling path-
ways related to cell growth and viability, cytoskeletal
organisation, cell migration, and apoptosis (reviewed in
[37]). In adult life, ephrin upregulation - particularly that
of ephrin B - has been correlated to vascular invasion,
blood vessel formation and sprouting by tumours, and
soluble Eph A receptors have been shown to inhibit
tumour angiogenesis [38]. EFNA3 has not previously
been associated with RA.
The adipokines, leptin and ANGPTL-4, are secreted
mainly by the liver and adipocytes, and their original role
as primary energy regulators in cell metabolism has pro-
gressively encompassed other functions including modula-
tion of immune and inflammatory processes as well as
angiogenesis [39,40]. Serum leptin levels have been
reported to be elevated in RA patients and to correlate to
accelerated atherosclerosis, thus potentially accounting for
increased incidence of cardiovascular disease afflicting RA
patients [41,42]. ANGPTL-4 has likewise been linked with
arthritis because it was identified in a gene expression pro-
filing analysis as one of the most highly expressed genes in
early CIA, a widely used mouse model of RA. Moreover,
ANGPTL-4 transcript has been reported to localise to
stromal fibroblast-like cells adjacent to blood vessels in the
mouse arthritic tissue, confirming that - like human RA
FLS - murine RA FLS also secrete ANGPTL-4 [43].
Although ANGPTL-4 and leptin have previously been
reported to be upregulated by hypoxia in RA FLS, the
study by Del Rey and colleagues did not investigate the
involvement of HIFs or cytokines in adipokine expression
by RA FLS [31]. We demonstrated for the first time that
these hypoxia-regulated genes were differentially regulated
by HIF isoforms under hypoxic conditions, with leptin
being primarily HIF-2 dependent, whereas ANGPTL-4
and VEGF were both HIF-1 and HIF-2 dependent, and
EFNA3 was induced mainly by HIF-1. We have recently
shown that these genes are similarly regulated in osteoar-
thritis and RA FLS by HIFs and prolyl hydroxylase-2, but
not in normal HSF, suggesting that this is a pathological
feature of synoviocytes from both diseases [44]. Once we
had established the relative contribution of HIF isoforms
to the hypoxic induction of the adipokines and EFNA3 in
RA FLS, we proceeded to investigate the regulation of
HIFs by cytokines alone and in combination with hypoxia,
as has been done before for HIF-1 and Th1 cytokines [21]
but not for Th2 cytokines and HIF-2. Th1 and Th2 cyto-
kines were previously reported to have differential effects
on HIF isoforms in macrophages, with Th1 cytokines
inducing HIF-1 and Th2 cytokines inducing HIF-2 [15],
but a similar relationship has not been established in RA
FLS. We demonstrated that HIF-1 was activated by Th1
cytokines, but not when RA FLS were stimulated with
Th2 cytokines. In contrast, HIF-2 expression was unaf-
fected by cytokine stimulation of either kind, thus high-
lighting a redundant role of HIF-2 in mediating cytokine-
induced angiogenic responses in RA FLS.
Interestingly, unlike the induction by Th1 cytokines, we
found that prolonged hypoxia reduced HIF-1a mRNA
levels although HIF-1a protein was concomitantly upregu-
lated. The downregulation of HIF-1a in hypoxia has been
described before in a human lung epithelial cell line
(A549) and is thought to be due to message destabilisation
by a naturally occurring antisense to HIF-1a, aHIF [29,45].
aHIF is therefore possibly responsible for hypoxia-
mediated downregulation of HIF-1a in RA FLS. HIF-2a
mRNA was also downregulated by hypoxia in our study;
however, as aHIF is complementary only to the 3’-UTR of
HIF-1a but not to any part of HIF-2a, aHIF may not
explain the hypoxia-mediated inhibition of HIF-2a
observed in our study. We are currently investigating the
role of aHIF in hypoxic and cytokine-stimulated RA FLS.
Our study thus confirms previous studies reporting that
HIF-1 represents a convergence point for inflammatory
and hypoxic signalling in RA FLS, since we found that
both Th1 cytokines and hypoxia induced HIF-1 protein as
previously reported and this effect was additive when cells
were co-stimulated [21]. We extended existing studies by
showing additive effects of Th1 cytokines and hypoxia at
the HIF-1 DNA binding activity level. Surprisingly, this
cytokine-mediated increase in HIF-1 activity did not
necessarily lead to induction of the four chosen down-
stream HIF-1 target genes in either normoxic or hypoxic
RA FLS. In agreement with previous work [18,22], we
found that VEGF was induced in a HIF-1-dependent man-
ner by both of the Th1 cytokines tested in an additive
(TNFa) and synergistic (IL-1b) fashion with hypoxia, as
would be expected if both stimuli converge on HIF-1 with
subsequent downstream target gene induction. Similarly,
EFNA3 was induced by Th1 cytokines, albeit modestly, in
a HIF-1-dependent manner, with IL-1b exerting an addi-
tive effect on EFNA3 expression in hypoxia. In contrast
however, when TNFa were added to supernatants of RA
FLS cultured under normoxic or hypoxic conditions, a
strong negative effect on RA FLS-mediated expression of
ANGPTL-4 was observed, despite the ability of Th1 cyto-
kines to induce large amounts of active HIF-1 protein.
Expression of the leptin gene, which was predominantly
regulated by HIF-2, was also inhibited by TNFa in hypoxic
RA FLS. These negative effects on adipokine expression
were not HIF mediated, as we demonstrated with siRNA
oligonucleotides against HIF isoforms. A complex picture
therefore emerges from our study, in which angiogenic
HIF target gene expression does not necessarily correlate
positively with the level of HIF activity as is the case for
VEGF in RA FLS.
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The suppressive effects of combined hypoxia and
TNFa on angiogenesis were further reflected in our
findings that supernatants from RA FLS subjected to
both stimuli did not induce tubule formation by
HMEC-1 cells in a matrigel assay above controls. This
observation could be due to the downregulation of
potent mediators of synovial angiogenesis; for instance,
adipokines. In contrast, supernatants from RA FLS sti-
mulated with either TNFa or hypoxia as single stimuli
induced angiogenesis above that of unstimulated cells,
with hypoxia having the greatest effect on angiogenesis.
These data suggest that the development of tubules is
induced in areas of the RA synovial tissue where either
inflammation or hypoxia dominates but is suppressed
where inflammation and hypoxia co-exist, in spite of
significant amounts of TNFa-induced HIF-1 and VEGF.
Our study confirmed that IL-4 stimulated RA FLS
express VEGF in concordance with previous literature
[46], but also highlighted a novel finding that IL-4
strongly induced ANGPTL-4 expression in a HIF-inde-
pendent manner under both normoxia and hypoxia. In
contrast, we found that IL-4 could completely abrogate
hypoxia-induced leptin expression by RA FLS. In agree-
ment with a study where IL-4 was shown to be proangio-
genic in murine lungs in vivo under hypoxic conditions
[47], we found supernatants from RA FLS co-stimulated
with IL-4 and hypoxia to have even stronger functional
angiogenic activity than supernatants from cells stimu-
lated with IL-4 alone. These supernatants contained
much less VEGF protein than supernatants from TNFa
and hypoxia-stimulated cells.
In contrast to VEGF, the levels of ANGPTL-4 present in
the RA FLS supernatants correlated with the degree of
tubule formation by HMEC-1. ANGPTL-4 has previously
been shown to stimulate tubule formation in a human
umbilical vein endothelial cell-based matrigel assay in the
absence of additional growth factors [43] and to induce
anti-apoptotic activity in human vascular endothelial cells
[48]. Moreover, ANGPTL-4 can induce a proangiogenic
response in the chicken chorio-allantoic membrane, an
effect that was shown not to require the presence of VEGF
[49]. The presence of high levels of ANGPTL-4 might
therefore contribute to the proangiogenic effects observed
in the supernatants from IL-4-stimulated RA FLS. Simi-
larly, the observed reduction in angiogenesis with hypoxia
and TNFa-treated cell supernatants, when compared with
effects of hypoxic supernatants, may be a consequence of
adipokine downregulation by TNFa.
This is not the first time that negative regulation of
angiogenic mediators by Th1 cytokines has been
described in RA FLS. Recent work demonstrates a nega-
tive effect of IL-1b on matrix metalloproteinase-13
expression in hypoxic RA FLS [50]. In contrast to the
HIF-independent downregulation of adipokines that we
observed in hypoxic RA FLS, the work by Lee and collea-
gues demonstrated the involvement of HIF-1 in hypoxia-
mediated downregulation of matrix metalloproteinase-
13. Our data suggest that other overriding signalling
pathways are induced in RA FLS, which can circumvent
the strong induction of HIF-1 following stimulation with
combined Th1 cytokines and hypoxia. This could possi-
bly involve PPAR-a and PPAR-g, established regulators
of ANGPTL-4 in adipose tissue [51,52]. In addition to
peroxisome proliferator-activated receptor response
elements in the promoter region of ANGPTL-4, trans-
forming growth factor b has been shown to regulate
ANGPTL-4 via an enhancer element located ∼8 kb
upstream of the transcriptional start site involving
SMAD3, ETS1, RUNX, and AP-1 transcription factors
[53,54]. We are presently investigating the signalling
routes by which TNFa exerts its negative effects on adi-
pokines in RA FLS.
The ability of TNFa to inhibit ANGPTL-4 expression
was specific for RA FLS because normal HSF stimulated
with the same concentration of TNFa exhibited a strong
induction of ANGPTL-4. In contrast, the ability by IL-4
to upregulate ANGPTL-4 was shared by both RA FLS
and HSF. These observations suggest that the inhibitory
effect of TNFa is mediated via a decline in ANGPTL-4
gene expression, and moreover that it may be a disease-
specific effect. Decreased expression of ANGPTL-4
might contribute to the transformed phenotype that
characterises RA FLS [4,25]. Although ANGPTL-4 was
identified in a gene expression profiling analysis as one of
the most highly expressed genes in early CIA (day 28),
this expression subsided with time (day 49) [43] - per-
haps suggesting that RA FLS lose the ability to express
ANGPTL-4 as disease progresses, with possible impact
on blood vessel formation. The RA FLS we used are from
patients with established RA of long duration.
The process of blood vessel maturation from immature
vessels involves recruitment of perivascular cells, assem-
bly of the basement membrane and establishment of
tight and adherens junctions. Failure to form functional
mature vessels is known to contribute to oedema forma-
tion, swelling and inflammation in RA joints (reviewed in
[55]). Interestingly, recent work in angptl-4-deficient
mice has shown that ANGPTL-4 is important in vessel
maturation because mice lacking ANGPTL-4 exhibited
disruption of endothelial adherens junctions and pericyte
coverage, with impaired angiogenesis and vascular leak-
age as a result [56,57]. RA synovium contains a signifi-
cant fraction of neoangiogenic, immature and leaky
blood vessels that may be observed from the early stages
of RA [6]. The presence or density of immature vessels is
significantly increased in patients with longer disease
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duration, higher activity and severity, and stronger
inflammatory cell infiltration [6]. Interestingly, immature
vessels are depleted in response to anti-TNF therapy,
highlighting the co-dependency of angiogenesis and
inflammation [6]. Based on our findings we speculate
that in areas of the synovium where hypoxia and Th1-
driven inflammation co-exist there would be an exces-
sive, pathological HIF-1-mediated response with elevated
VEGF production, yet suppression of functional angio-
genesis with immature vessel formation, a well-known
effect of elevated VEGF [58]. If there is suppression of
expression of angiogenic factors necessary for vessel
maturation such as ANGPTL-4, the final outcome may
thus be leaky and immature vessels. This is supported by
a study showing that ANGPTL-4 decreases VEGF-
induced vascular leakage in the Miles assay, which mea-
sures extravasation of Evans Blue dye from vessels in
mouse back skin [58]. In contrast, Th2 cytokine therapy
might ameliorate inflammation in CIA in hypoxic areas
of the synovium, through the formation of mature vessels
by overriding the local anti-angiogenic effects of hypoxia
combined with Th1 cytokines and by inducing factors
such as ANGPTL-4 resulting in vessel maturation. Eluci-
dating the difference in the angiogenic gene profile
induced by Th1 and Th2 cytokines in hypoxia is thus of
great importance, because such differences may account
for the pathological ratio of mature to immature vessels
in RA depending on the type of angiogenic factors they
induce or inhibit. We are currently investigating the sig-
nificance of TNFa-induced inhibition of adipokines in
RA FLS-mediated angiogenesis, with specific interest in
defining the function of ANGPTL-4.
Conclusion
In the present study we have demonstrated that Th1
cytokines in combination with hypoxia are not suffi-
cient to induce angiogenic activity by RA FLS despite
inducing HIF-1 activation and VEGF production. In
contrast, Th2 cytokines induce proangiogenic activity
in normoxia and hypoxia, despite their inability to acti-
vate HIFs, highlighting the complex relationships
between hypoxia, angiogenesis and inflammation in
RA. Furthermore, we have unmasked novel inhibitory
effects of TNFa in combination with hypoxia on alter-
ing gene expression and on the functional angiogenic
properties of RA FLS that have not been described
elsewhere. These negative effects may influence the
degree of pathological vessel formation in the RA
synovium and hence the clinical response of RA
patients on anti-TNFa treatment. Finally, our results
highlight the potential role of ANGPTL-4 in regulating
RA synovial angiogenesis through its differential regu-
lation by proinflammatory and anti-inflammatory
cytokines.
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